June 3rd 2023
By Alex Biese
Participants in the RESTORE study, results of which were presented this weekend at ASCO, saw “significant improvements” in depression and anxiety symptoms after using the Attune app.
June 3rd 2023
By Lindsay Fischer
Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.
June 3rd 2023
By Brittany Lovely
Findings from the monarchE trial presented at ASCO showed that for patients with hormone receptor–positive, HER2-negative, high-risk, early breast cancer, Verzenio provided “consistent treatment benefit.”
June 3rd 2023
By Darlene Dobkowski, MA
Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.
June 3rd 2023
By Kristi Rosa
The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.
June 2, 2023 5:00 PM
By Debbie Legault
June 1, 2023 9:00 PM
By Linda Cohen
June 1, 2023 5:00 PM
By Elizabeth McSpadden
May 31, 2023 11:00 PM
By Steve Rubin
May 12, 2023 7:00 PM
By Bryana Tanner
May 11, 2023 9:00 PM
By Robert Trebor
May 8, 2023 9:00 PM
By Denise Sirchie
May 4, 2023 1:00 PM
By Chester Freeman
An App Improved Anxiety, Depression Symptoms in Patients With Cancer
Imjudo-Imfinzi Regimen Improves Survival With Manageable Side Effects in Liver Cancer Subset
Patients with HR+, HER2–, Early Breast Cancer Experienced Survival Improvement with Verzenio Plus Endocrine Therapy
Radium-223 Safe and Effective to Treat Metastatic Castration-Resistant Prostate Cancer